Stories
Biocon Malaysia Secures UK Approval for Semglee Fill-Finish Unit
C
CNBC TV18•25-09-2026, 10:11
Biocon Malaysia Secures UK Approval for Semglee Fill-Finish Unit
- •Biocon Ltd.'s Malaysian subsidiary received approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its new Semglee (insulin glargine) fill-finish unit.
- •The approval pertains to the insulin manufacturing facility in Malaysia, enhancing Biocon's global production capabilities for Semglee.
- •Biocon's MD and CEO, Shreehas P Tambe, anticipates the company's insulin business will soon reach $1 billion in revenue, driven by strong demand and new products like aflibercept.
- •The company boasts a portfolio of over 30 biosimilars, including Aflibercept, trastuzumab, and pegfilgrastim, and targets double-digit revenue growth in this segment.
- •Biocon aims for mid-20% margins by improving the profitability of its recently combined biologics and generics businesses, which previously saw lower margins in generics.
Key Questions Answered
The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK approved the new drug product fill finish unit for Semglee (insulin glargine) at Biocon's manufacturing facility in Malaysia.
Biocon reported a net profit surge to ₹141 crore from ₹31.4 crore the previous year, with total revenue increasing 16% to ₹4,336 crore. Its EBITDA also rose 10.6% to reach ₹847.2 crore, and the profit margin expanded to 19.54%.
Biocon MD and CEO Shreehas P Tambe stated that the company's insulin business can reach the $1 billion revenue mark soon, driven by strong demand and growth in newer products such as aflibercept.
